James Marion

James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

OncoSec Medical Inc. (NASDAQ:ONCS) Falls After Pricing Offering

OncoSec Medical Inc. (NASDAQ:ONCS)

OncoSec Medical Inc. (NASDAQ:ONCS) shares fell 12.9% after the biotechnology company announced it has entered into a definitive purchase agreement with accredited investors. Pursuant to the agreement, the company is to issue 5.3 million shares of common stock at $1.34 a share.

OncoSec Medical Inc. (NASDAQ:ONCS)

Public Offering

The company has also agreed to issue the investors unregistered warrants, expiring in 5.5 years, for the purchase of up to 3.9 million shares of common stock at $1.25 a share. OncoSec Medical expects gross proceeds of $7.1 million from the offering.

OncoSec Medical Inc. (NASDAQ:ONCS) expects net proceeds of approximately $6.2 million after the deduction of fees and other expenses. The offering should close on or about October 25, 2017.

Net proceeds from the offering are to be used for working capital, general corporate purposes, and for ongoing clinical research and development programs. The pricing of the purchase agreement appears to have spooked investors as seen by the stock’s failure to rise above $1.30.

Prior to the announcement of the offering, OncoSec Medical Inc. (NASDAQ:ONCS) had been on an impressive run after a string of positive clinical trial results. However, the uptrend appears to be losing momentum – threatening to push the stock to multi-year lows.

Clinical Trials

OncoSec has been trading higher in the market following the presentation of positive Phase 2 data for it lead candidate drug ImmunoPulse IL-12 for the treatment of metastatic melanoma. Phase 2 study results indicate that only 10% of the patients treated with the drug in combination with pembrolizumab experienced serious adverse events

Preliminary trial results also indicate that ImmunoPulse IL-12 has the potential to trigger key immunologic events.

“Collectively, these study findings reinforce the combination of ImmunoPulse IL-12 and pembrolizumab to address a significant unmet medical need in melanoma patients who are unlikely to respond to anti-PD-1 therapies,” said Punit Dhillon, CEO, and President of OncoSec.

OncoSec Medical Inc. (NASDAQ:ONCS) is to present additional data in ongoing Phase 2 combination study at the upcoming Society for Immunotherapy of Cancer Annual Meeting.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Atossa Genetics Inc (NASDAQ:ATOS)

Atossa Genetics Inc (NASDAQ:ATOS) Continuing Upward Move

Atossa Genetics Inc (NASDAQ:ATOS)

Atossa Genetics Inc (NASDAQ:ATOS) stock fell on the open then rallied on heavy volume to finish the day with a 29% gain – closing at $0.62. ATOS shareholders have seen the stock move up by 24% for the week on the back of a company announcement that the Ernest Mario School of Pharmacy at Rutgers, The State University at New Jersey, plans to conduct a study utilizing Atossa’s intraductal microcatheter technology. Atossa Genetics is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions.

Atossa Genetics Inc (NASDAQ:ATOS)

Rutgers Study

The Rutgers program is in the research and development phase and has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body. Studies demonstrating safety and efficacy, among other things, and regulatory approvals will be required before commercialization. The Rutgers researchers believe that directly administering drugs into the breast duct where breast cancer grows, by inserting microcatheters into the nipple, is a better alternative than systemic administration, because the drugs will be directly delivered to the tissue. The Rutgers program uses a unique directed delivery system comprised of nanoscale pharmaceutical carriers loaded with single drugs.

Steven Quay, MD, PhD, Atossa CEO and President of Atossa Genetics Inc (NASDAQ:ATOS) stated in a press release “We are encouraged that a leading research institution like Rutgers recognizes the potential merit of our microcatheter technology. Atossa fully supports additional research utilizing our patented microcatheter technology,”.

ATOS Stock Performance

Although down over 65% for the year, in the past quarter ATOS shareholder have seen their stock gain over 60%. Currently ATOS stock is about double its 52-week low of $0.32 but still far from its 52-week high of $2.60.

Atossa Genetics Inc (NASDAQ:ATOS) has posted no sales over the past three years. On the plus side, it has seen shrinking losses over the past four years and in 2016 reported a per share loss of (-$2.16). However ATOS shareholders should be aware that the number of outstanding shares has increased every year – resulting in shareholder’s equity being diluted. According to reports, ATOS has a consensus 1-year price target among analysts of $26.25.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ATOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) Trades Higher

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC)

BITCOIN SERVICES I COM USD0.001(OTCMKTS:BTSC) shares received a boost after bitcoin gained more than 5% in Friday’s trading session to close in on a new record high of $6000. The stock gained 8.25% to end the week at $0.0667.

Bitcoin’s impressive run has seen its market grow to about $100 billion. Initial Coin Offerings have achieved an average return of 790% over the past six months.

BITCOIN SERVICES I COM USD0.001(OTCMKTS:BTSC)

BTSC Stock Performance

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) is currently trading near a key support level at $0.06, below which the stock faces the risk of erasing a good chunk of gains accrued since the start of the year. The stock is up by more than 400% for the year after benefiting from the growing popularity of digital currencies.

However, the stock is currently trading in a range after dropping from $0.21 to current trading levels. Failure of Bitcoin Services to issue updates about its operations and prospects in the bitcoin mining business has been the biggest undoing in fueling investor concerns.

Business Update

Investor’s confidence has taken a hit as most of them switch their attention to other stocks that provide detailed information about their operations. The last update came in August when the company unveiled a new corporate website and announced the launch of its digital cash Dash that can be used to make instant private payments online or in-store using secure and open source platform.

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) also announced the creation of a new subsidiary dubbed Crypto Capital Corp that was to develop a Crypto-currency wallet. The big plan was to provide a way for people to safely store multiple digital currencies in one location.

In May, the bitcoin manufacturing company announced it had begun mining Monero, one of the top digital currencies with a market cap of over $300 million. Early this year Bitcoin Services purchased four Antminer S9 bitcoin miners as it sought to support its growth prospects.

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) operates three core business – bitcoin escrow services, bitcoin mining, and blockchain software development. Its principal products and services are the mining of bitcoin as well as providing escrow services for buyers and sellers and bitcoin.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BTSC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) Drops 37%

Immune Pharmaceuticals Inc. (NASDAQ:IMNP)

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) felt the wrath of Wall Street after announcing the pricing of an underwritten public offering from which it expects gross proceeds of $18 million. Shares of the biopharmaceutical company fell 37.42% to end Thursday’s trading session at $37.4%.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP)

Investors Reaction

The sell-off came on growing concerns that the public offering could plunge the stock into more debt. Investors also reacted to concerns that the offering will result in further dilution of the stock. Thursday’s sell-off plunged the stock to multi-year lows.

The stock is currently trading in a strong downtrend after underperforming the overall industry for the better part of the year. IMNP is down by more than 70% for the year as its sentiments on Wall Street continue to turn from bad to worse.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) offering comprises of units priced at $1,000 a unit. Each unit on offer comprises of one share of Series E Convertible preferred stock and 982 warrants for the purchase of one share of the company. The Warrants are exercisable at $1.10 and expire in seven years.

Immune Pharmaceuticals Pipeline

The pricing of the public offering comes at a time when Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has narrowed its focus on two promising products. The company is currently conducting Phase II clinical trial on its lead candidate drug Bertilimumab, for the treatment of patients suffering from bullous pemphigoid. The biopharmaceutical company is also investigating the drug for the treatment of ulcerative colitis.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) is fresh from reporting positive Phase 2 clinical trials for moderate to severe bullous pemphigoid clinical trials. Trial results from six patients enrolled in the trial indicate a decline in patients total activity score by 85%.

“If bertilimumab can substantially reduce or perhaps even eliminate the need for systemic corticosteroids in the treatment of bullous pemphigoid and their significant toxicity in this elderly population, it will be a major step forward in the management of what is the most common blistering disease,” said Dr. Neil Korman.

According to the Chief Executive Officer, Elliot Maza, the topline preliminary results support the company’s strategy of focusing human capital and financial resources on Bertilimumab. Immune Pharmaceuticals Inc. (NASDAQ:IMNP) is currently preparing to enroll patients in Phase 2 open-label of BP trial.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMNP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) Slumps 29%

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)

Shares of Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) fell 29.7% after the biopharmaceutical company announced the pricing of an underwritten public offering of 3.5 million American Depository Shares at $5 per ADS. The company has also granted underwriters a 30-day option for the purchase of additional 522,000 ADS shares.

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)

The company expects gross proceeds of $17.4 million from the offering – assuming underwriters don’t exercise the option to purchase additional shares. Net proceeds from the offering are to be used to fund ongoing clinical development efforts as well as for working capital and other general corporate purposes. The offering should close on or about October 20, 2017, subject to satisfaction of customary closing conditions.

Akari Investors’ Reaction

News of the public offering has not gone well with investors given that, in addition to plunging the company into more debt, the offering will lead to further dilution of the stock. Wednesday’s sell-off accompanied a downtrend that has gripped the stock in recent weeks.

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) has shed more than 40% in market value over the past month as sellers continue to push the stock lower. The stock is down by more than 30% for the year and on the brink of dropping to multi-year lows.

Amidst the recent sell-off, William Blair upgraded shares of Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) from ‘Market Perform’ to ‘Outperform’ in a research note to investors. The upgrade came at a time when the stock was trading at the $8.80 per share. The firm, at the time, said the shares of the biopharmaceutical Company were undervalued given the value proposition on the development of candidate drug Coversin.

Coversin Development

Separately, the developer of inhibitors for acute and chronic inflammation has enrolled three additional patients in the ongoing Phase II COBALT clinical trial of Coversin, in patients with paroxysmal nocturnal Hemoglobinuria (PNH). The addition brings to eight the total number of patients under trial. Four of the patients have already moved to the long-term safety study, Converse.

Akari Therapeutics is to issue an update on al PNH patients at the American Society of Hematology Annual Meeting to be held next month. The company has also announced plans to advance Coversin towards Phase III trials in naïve PNH patients. William Blair puts the success probability of the PNH program at 55% with an estimated peak U.S. sales target of $500 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AKTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

DarioHealth Corp (NASDAQ:DRIO)

DarioHealth Corp (NASDAQ:DRIO) App Pushes Shares Higher

DarioHealth Corp (NASDAQ:DRIO)

DarioHealth Corp (NASDAQ:DRIO), a developer of App-based diabetes management systems, shares are up over 30% with an hour left in the trading day. Volume for the nano-cap healthcare technology firm are massive. DRIO stock is listed with an average daily trading volume of less than 30,000 shares traded per day. Before the end of trading today already over six million shares have been traded.

NASDAQ:DRIO

DarioHealth Business Model

Israeli-based DarioHealth Corp (NASDAQ:DRIO) develops proprietary technologies using smart phones and other mobile devices. Its flagship product is Dario, a mobile, real-time, cloud-based, diabetes management solution based on a multi-feature software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device.

Today DarioHealth Corp (NASDAQ:DRIO) announced that it received the CE Mark for its Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System. The news ensures that consumers, beginning in the UK market, will be able to receive the same quality user experience with DarioHealth on the latest Apple devices, including the brand-new iPhone 8.

Erez Raphael, Chairman and CEO of DarioHealth Corp (NASDAQ:DRIO), commented, “We’ve been working tirelessly to bring forth a solution that would meet the rigorous standards required to achieve the CE Mark. We are proud that our organization worked with agility to ensure connectivity to the latest Apple devices. This significant milestone will allow us to open to a whole new market segment and reengage with former-Dario users who now have the newest Apple devices.”

DRIO Stock

DRIO stock tried to break through the $3 level back in May but without success. The shares then slid and traded in a $1.80-$2.00 range for the last several weeks. Shares are still down over 40% YTD and well below their 52-week high of $4.70. DRIO stock has a $4.25 price target by the lone analyst that covers the shares and assigns DRIO a rating of “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Social Reality Inc. (NASDAQ:SRAX)

Social Reality Inc. (NASDAQ:SRAX) Affirms Commitment

Social Reality Inc. (NASDAQ:SRAX)

Social Reality Inc. (NASDAQ:SRAX) shares nearly doubled in value after the advertising technology company announced it had engaged the services of financial advisors to explore strategic alternatives for the SRAXmd business. The stock was up by 70.7% in Tuesday’s trading session to end the day at $4.90 a share.

SRAX Stock Performance

Tuesday’s rally helped affirm a bullish run that began late last month, which has seen the stock bounce from multi-year lows, near the $1 a share mark. While the stock is still down by more than 10% for the year, it continues to trade in an uptrend after erasing some losses.

Renewed investors interest in the advertising technology company comes on growing confidence surrounding the company’s commitment to growing shareholder value. One of the strategic alternatives that Social Reality Inc. (NASDAQ:SRAX) is exploring for the SRAXmd business is strategic acquisitions that have the potential to support the core business.

Social Reality is also considering spinning off some of its business units into its own public company in pursuit of shareholder value. SRAX works with healthcare and pharmaceutical companies to engage healthcare professional’s patient and caregivers through mobile and digital advertising. The firm boasts of a patent-pending platform that is designed to allow for event-triggered response for targeting HCP facilities.

“The ability to positively impact patient outcomes through real-time mobile targeting to professionals is the future of Non-Personal Promotion. We have delivered 100% year-over-year revenue growth for SRAXmd since the rollout of MD products in 2014. Non-Personal Promotion continues to evolve at a more rapid rate than traditional methodologies,” said Chief Innovations Officer Erin DeRuggiero.

Demand Side Platform Acquisition

A move to pursue strategic alternatives for the SRAXmd business follows the acquisition of Demand Side Platform, a technology firm focused on marketing experimentation and optimization of brands. The privately-held firm has helped develop a unique DSP with Real-Time Bidding and targeting capabilities that Social Reality Inc. (NASDAQ:SRAX) expects to bond well with SRAX platform.

“Not only does the technology acquired complement our DSP, but it will also be powerful and valuable to the buy-side of our business serving brands and agencies,” said CEO, Christopher Million.

Separately, Social Reality Inc. (NASDAQ:SRAX) has appointed Veteran Matt Weiss to its Board of Directors. He joins the company having worked for some of the largest advertising agencies in the world such as Havas Worldwide and McCann World group.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SRAX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

MagneGas Corporation (NASDAQ:MNGA)

MagneGas Corporation (NASDAQ:MNGA) Receives $1.58 Million Order

MagneGas Corporation (NASDAQ:MNGA)

MagneGas Corporation (NASDAQ:MNGA) shares fell 6.10% after the clean technology company announced the sale of a gasification unit for $1.58 million. The order builds on a previously announced consulting agreement in Europe where the company is aggressively pursuing sales opportunities.

MagneGas Corporation (NASDAQ:MNGA)

Europe Sales Push

Investor’s reaction, however, has not been good even as the company moves to pursue new sales opportunities beyond Germany. The stock continues to languish near all-time lows after remaining under pressure for the better part of the year. MagneGas Corporation is down by more than 80% for the year.

According to the Chief Executive Officer, Ermanno Santilli, the sale is a milestone achievement as it helps build a pipeline that the company will be able to leverage in the coming months. The unit will be placed in the Nordics region for the production of MagneGas2 from Butanol. It may also be placed in continental Europe at large steel mill.

The sale builds on a$1.9 million deal that MagneGas Corporation (NASDAQ:MNGA) inked early in the month for a gasification unit for the production of MagneGas2 in European markets.

“We were impressed by the quality of the opportunity pipeline that our distributor in Europe has developed in a relatively short period of time and this latest opportunity demonstrates continued success in penetrating a customer base which is ready for a replacement product to legacy acetylene,” commented MagneGas CFO Scott Mahoney.

MagneGas Consulting Contract

In addition, MagneGas Corporation has been contracted by a European partner to provide consulting services focused on identifying and validating the application of their proprietary technology in Europe. The value of the contract is $500,000 and could increase to $1 million – depending on the scope.

Under terms of the deal, the clean technology company is to gain access to an approved range of testing facilities that are approved for waste streams. MagneGas Corporation (NASDAQ:MNGA) is also tasked with the responsibility of determining the economic value and technical feasibility of new gasification and sterilization solutions in Europe. Mr. Mahoney expects the contract to further accelerate the company’s commercialization efforts in Europe.

“There is significant pent-up demand in Europe, due to the regulatory environment and other factors, which represents an immediate and sizable market opportunity for MagneGas,” said Mr. Mahoney.

Separately, MagneGas Corporation (NASDAQ:MNGA) has signed a Letter of Intent for the acquisition of an independent industrial gas and welding supply business, expected to generate over $1.6 million in annual revenues.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MNGA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Aethlon Medical, Inc. (NASDAQ:AEMD) Partners with iBio Inc.

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical, Inc. (NASDAQ:AEMD) shares fell 3.88% after announcing the formation of a large scale production collaboration agreement with iBio, Inc. (NYSE AMERICAN: IBIO). The primary goal of the collaboration is to advance the large-scale production of Galanthus nivalis agglutinin (GNA), a plant-derived lectin in Aethlon’s Hemopurifier.

Aethlon-iBio Partnership

According to iBio President, Barry Holtz, a collaboration of the two companies is an ideal combination for the delivery of new therapeutic approach for pandemic diseases and biothreats. Researchers from the two companies have already completed a feasibility study that sought to produce highly active recombinant GNA with iBio’s plant technology.

Jim Joyce, Chairman and CEO of Aethlon stated, “The production of recombinant GNA in iBio’s large-scale manufacturing facilities establishes a pathway for us to access a consistent, high-quality supply that can support our long-term clinical and commercialization objectives,”

Aethlon Hemopurifier is a first-class therapeutic device that the U.S. Food and Drugs Administration (FDA) has awarded Expedited Access Pathway for the treatment of life-threatening viruses. The biotechnology company has already validated the device’s ability to capture a broad spectrum of pandemic influenza viruses as well as mosquito-borne viruses and deadly hemorrhagic viruses.

Aethlon Medical, Inc. (NASDAQ:AEMD) is currently investigating the potential use of the Hemopurifier to reduce the presence of tumor-derived exosomes which suppresses immunity and leads to a spread of metastasis in cancer patients.

AEMD Stock Performance

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon’s stock underperformance continued in Monday’s trading session as the stock came under pressure from sellers. The stock is currently trading at multi-year lows after losing more than 70% in market value since the start of the year. The stock dropping below the $1 a share is already arousing concerns about the stock’s continued listing status in the market.

Last week Aethlon Medical, Inc. (NASDAQ:AEMD) issued a statement indicating that the NASDAQ had formally notified it that it complied with all the applicable required listing requirements. While one of the requirements is a $2.5 million stockholder equity position, the share price is also required to be above $1 a share for continued listing

Aethlon Medical, Inc. (NASDAQ:AEMD) is in need of new catalysts if it is to gain favor among investors and bounce back from current trading levels.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AEMD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Recon Technology, Ltd. (NASDAQ:RCON)

Recon Technology, Ltd. (NASDAQ:RCON) Pops!

Recon Technology, Ltd. (NASDAQ:RCON)

Recon Technology, Ltd. (NASDAQ:RCON)

By 3 PM EST Recon Technology, Ltd. (NASDAQ:RCON) shares had traded hands over 20 million times. Its 30-day, daily trading average is 20,140 which makes today’s volume figure over 1,200 times the average. At the time of this writing RCON shares are trading around the $2.28 level after closing Friday at $1.02. The catalyst for the 120%+ move hat it has signed a three-year strategic cooperation agreement (“Agreement”) with Beijing OriginWater Purification Engineering Technology Co., Ltd (“BOW Engineering”). According to terms of the agreement, Recon Technology and BOW Engineering will collaborate and promote advanced sewage treatment technology in the Chinese oilfield markets. Together they will also supply solutions and services of superior quality and effectiveness to tackle industrial water pollution.

Mr. Shenping Yin, CEO of Recon Technology stated in the press release “Chinese government as well as large oil companies are dedicated to protecting the environmental during oil production and seeking more efficient techniques and equipment to realize cost-saving and meet increasingly stringent environmental protection requirement… With its abundant market experience, deep insights and visions in oilfield markets, and support of BOW’s team of specialists, we believe Recon will maintain research and technological advantages and deliver better performance.”

Beijing OriginWater Technology Co. Ltd. addresses China’s three main water challenges: water pollution, water shortage and confidence in the drinking water supply. BOW is one of the world largest water-membrane technology enterprises and is also a leading developer of environmental protection enterprises.

Before today’s trading, RCON stock’s 52-week high was $1.93, reached late last year. Its 52-week low was $0.64 which was reached last month. 15% of the share’s float is held by short-sellers – a number that will likely decline given the positive news. Insiders own 53% of the shares and institutions own less than 1%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RCON and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.